BCMA-Specific CAR-Expressing T Lymphocytes Myeloma Trials

BCMA-specific CAR-expressing T Lymphocytes is a BCMA targeted CAR T Cell therapy being developed at the Fred Hutchinson Cancer Research Center.

SparkCures ID	333
Generic Name	BCMA-Specific CAR-Expressing T Lymphocytes
Treatment Classifications	CAR T Cell
Treatment Targets	B-Cell Maturation Antigen (BCMA)

All Clinical Trials

View all active clinical trials around the US.

View Trial

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

View Trial

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

View Trial

Smoldering Myeloma

No active clinical trials

Monoclonal Gammopathy of Undetermined Significance (MGUS)

No active clinical trials

December 07, 2019

Eight patients, with a median age of 64.5 (range, 50-70 years) and a median of 10 prior regimens (range, 4-23), were screened, and seven patients have been treated.
High-risk features were present in 75% of patients
Following 3 oral doses (run in) of JSMD194, the percent of plasma cells expressing BCMA increased from 75% to 99% (7.6 to 98% pre, 75 to 100% post), soluble BCMA decreased by 2.0 fold (range 1.6 to 2.6 fold) after 3 oral doses, and BCMA antigen binding capacity increased from a median of 718 receptors to 13355 receptors per cell, or a median of 20-fold (range, 7.55-fold to 156.68-fold).
Among 6 assessable patients, the best overall response rate was 100% (5 VGPR, 1 PR), with 5/6 patients MRD negative by flow. At data cutoff of July 15, 2019, no patient has relapsed, with a median follow-up of 5 months (range 1-11 months).

BCMA-Specific CAR-Expressing T Lymphocytes